Is there a standard of care for relapsed AML?
Author:
- Bruno C. MedeirosBMBruno C. Medeiros
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 31 (4) , 384-386
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experienceAmerican Journal of Hematology, 2018
- Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine, 2018
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood, 2017
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyThe Lancet Oncology, 2017
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyThe Lancet Oncology, 2015
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS studyLeukemia, 2011
- Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapseBlood, 2009
- High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa groupLeukemia, 2006
- Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2005